Therapeutic Antibody Program
Alzheimer's Disease (early intervention)
Discovery/Pre-clinicalActive
Key Facts
Indication
Alzheimer's Disease (early intervention)
Phase
Discovery/Pre-clinical
Status
Active
Company
About AivoCode
AivoCode is a private, preclinical-stage biotech company founded in 2020 and based in San Francisco, CA. The company is developing a novel platform to discover molecular 'zip codes' that enable targeted delivery of neuroprotective and anti-inflammatory therapeutics to specific diseased areas of the brain and eye. Its pipeline includes a lead neuroprotection candidate and a therapeutic antibody program for an early Alzheimer's target, positioning it to address significant unmet needs in neurology and ophthalmology. The company is led by a team with deep experience in drug delivery, neuroscience, and startup ventures.
View full company profile